Wang Michael, Zhou Yuhong, Zhang Liang, Nguyen C Ann, Romaguera Jorge
The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, TX 77030-4009, USA.
Expert Rev Anticancer Ther. 2006 Jul;6(7):983-91. doi: 10.1586/14737140.6.7.983.
The ubiquitin-proteasome pathway plays a critical role in the regulated degradation of proteins involved in cell cycle control and tumor growth. Bortezomib (Velcade, formerly known as PS-341) is a potent proteasome inhibitor. In preclinical studies, bortezomib has demonstrated activity against a variety of B-cell malignancies by inducing apoptosis and sensitizing tumor cells to radiation or chemotherapy. Based on these findings, clinical trials have been conducted with bortezomib in B-cell non-Hodgkin's lymphoma. In these studies, bortezomib was generally well tolerated with manageable toxicities and showed promising clinical activity. Mantle cell lymphoma was significantly more sensitive to bortezomib than other non-Hodgkin's lymphomas. Bortezomib may have far-reaching potential in the treatment of B-cell non-Hodgkin's lymphoma.
泛素-蛋白酶体途径在参与细胞周期调控和肿瘤生长的蛋白质的调节性降解中起关键作用。硼替佐米（万珂，原称PS-341）是一种有效的蛋白酶体抑制剂。在临床前研究中，硼替佐米通过诱导细胞凋亡以及使肿瘤细胞对放疗或化疗敏感，已显示出对多种B细胞恶性肿瘤的活性。基于这些发现，已开展了硼替佐米治疗B细胞非霍奇金淋巴瘤的临床试验。在这些研究中，硼替佐米总体耐受性良好，毒性易于控制，并显示出有前景的临床活性。套细胞淋巴瘤对硼替佐米的敏感性显著高于其他非霍奇金淋巴瘤。硼替佐米在治疗B细胞非霍奇金淋巴瘤方面可能具有深远潜力。
